Journal
CLINICAL NEUROLOGY AND NEUROSURGERY
Volume 207, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.clineuro.2021.106736
Keywords
Epilepsy; Seizure; Mesenchymal stem cells; Cell therapy; Levetiracetam
Categories
Funding
- Ministry of Health of the Republic of Belarus [20120419, 20170004]
Ask authors/readers for more resources
Autologous mesenchymal stem cell therapy has been found to be safe and effective in drug-resistant epilepsy patients, improving symptoms such as anxiety and depression, with enhanced benefits when combined with levetiracetam. Repeated administration of MSCs has shown additional clinical benefits in reducing seizure frequency and epileptiform EEG activity.
Purpose: Epilepsy is defined as drug-resistant when existing anti-epileptic drugs (AED) are found to have minimal to no effect on patient's condition. Therefore the search and testing of new treatment strategies is warranted. This study focuses on the effects of autologous mesenchymal stem cells (MSC) in drug-resistant epilepsy patients within a Phase I/II open-label registered clinical trial NCT02497443. Materials/methods: A total of 67 patients was included (29 males, 38 females, mean age 33 +/- 1.3 yo). The patients received either standard treatment with AEDs, or AEDs supplemented with one or two courses of therapy with autologous bone marrow-derived MSCs expanded in vitro. MSC therapy courses were 6 months apart, and each course consisted of two cell injections: an intravenous infusion of MSCs, followed within 1 week by an intrathecal injection. Primary outcome of the study was safety, secondary outcome was efficacy in terms of seizure frequency reduction and response to treatment. Results: MSC injections proved safe and did not cause any severe side effects. In MSC group (n = 34), 61.7% patients responded to therapy at 6 months timepoint (p < 0.01 vs control, n = 33), and the number rose to 76.5% by 12 months timepoint. Decrease in anxiety and depression scores and paroxysmal epileptiform activity was observed in MSC group based on HADS and EEG, respectively, and MMSE score has also improved. Another observation was that concomitant administration of levetiracetam, but not other AEDs, correlated significantly with the success of MSC therapy. Second course of MSC therapy facilitated further reduction in seizure count and epileptiform EEG activity (p < 0.05 vs single course). Conclusions: Application of autologous mesenchymal stem cell-based therapy in patients with pharmacoresistant epilepsy demonstrated significant anticonvulsant potential. This effect lasted for at least 1 year, with repeated administration of MSCs conveying additional clinical benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available